Clinical Trials Directory

Trials / Completed

CompletedNCT01562782

Change of Fructose to Fat in South Asians

Fructose-induced Hepatic De Novo Lipogenesis in South Asians

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
39 (actual)
Sponsor
The Rogosin Institute · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).

Detailed description

South Asians, who originate from the Indian subcontinent and make up one-fifth of the world's population, are among the highest number who suffer from heart disease and diabetes. The results of many research studies suggest that genes play a role in developing heart disease and diabetes that is made worse by the diet in the United States. Fructose is a sugar widely used in the American diet, and when consumed, it is taken up by the liver and changed into fats through a process called de novo lipogenesis (DNL). The current study will compare this change into fats in the liver between South Asians and Caucasians. The participants will be screened on the initial visit, and on the second visit, the DNL response will be measured in the blood over four hours after drinking one sweetened beverage, containing half glucose, half fructose, similar to a soft drink. We expect that DNL in response to fructose intake is higher in South Asians when compared to Caucasians and may partially explain why South Asians have earlier heart disease and diabetes.

Conditions

Interventions

TypeNameDescription
OTHERFructose + Glucose BeverageConsumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.

Timeline

Start date
2012-04-02
Primary completion
2013-10-10
Completion
2013-10-10
First posted
2012-03-26
Last updated
2024-03-12
Results posted
2019-07-19

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01562782. Inclusion in this directory is not an endorsement.